MedPath

Glycerol phenylbutyrate

Generic Name
Glycerol phenylbutyrate
Brand Names
Ravicti
Drug Type
Small Molecule
Chemical Formula
C33H38O6
CAS Number
611168-24-2
Unique Ingredient Identifier
ZH6F1VCV7B
Background

Glycerol phenylbutyrate is a nitrogen-binding agent. Chemically, it is a triglyceride in which three molecules of phenylbutyrate are linked to a glycerol backbone. FDA approved on February 1, 2013.

Indication

Glycerol phenylbutyrate is a nitrogen-binding agent for the chronic management of adult and pediatric patients ≥2 years of age with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone.

Associated Conditions
Disorders of urea cycle metabolism
Associated Therapies
-
amgen.com
·

AMGEN REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS

Amgen reports Q3 2024 financial results: total revenues up 23% to $8.5 billion, GAAP EPS increased 62% to $5.22, non-GAAP EPS up 13% to $5.58, driven by strong product sales and pipeline investments.
forbes.com
·

The Recent Surge in Drug Costs and What Can Be Done About It

Healthcare costs are projected to rise 8-9% next year, driven by increased demand for outpatient care and unprecedented growth in pharmacy costs, particularly GLP-1 diabetes and weight loss drugs. Specialty drugs, though used by less than 2% of the population, account for 51% of drug benefit costs. The financial impact of GLP-1s on manufacturers is significant, with Novo Nordisk and Eli Lilly seeing substantial market capitalization growth. Demand for GLP-1s exceeds supply, leading to shortages and reliance on compounding pharmacies. High-cost specialty drugs for conditions like HIV and cancer are expected to grow to $1.5 trillion by 2033. Affordability concerns loom, with potential solutions including Medicare negotiation and increased competition among manufacturers.
© Copyright 2025. All Rights Reserved by MedPath